Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Articles

Page 1 of 40

  1. With the availability of first disease-modifying treatments, evidence on costs across the entire Alzheimer's Continuum, especially for early disease stages, becomes increasingly important to inform healthcare ...

    Authors: Eva Gläser, Ingo Kilimann, Moritz Platen, Wolfgang Hoffmann, Frederic Brosseron, Katharina Buerger, Marie Coenjaerts, Emrah Düzel, Michael Ewers, Klaus Fliessbach, Ingo Frommann, Maria Gemenetzi, Wenzel Glanz, Julian Hellmann-Regen, Enise I. Incesoy, Daniel Janowitz…
    Citation: Alzheimer's Research & Therapy 2025 17:142
    Content type: Research Published on:

  2. Photobiomodulation (PBM), which utilizes specific light wavelengths to regulate cellular metabolism, signal transduction, and gene expression, has emerged as a promising intervention for enhancing cognitive fu...

    Authors: Chunyan Ma, Yutong Ye, Xinyu Shi, Na Li, Zhiming Mu, Tao Tan, Huijuan Yin, Jianwu Dai, Yi Liu and Hongli Chen
    Citation: Alzheimer's Research & Therapy 2025 17:141
    Content type: Research Published on:

  3. Both electroacupuncture (EA) and repetitive transcranial magnetic stimulation (rTMS) possess the potential in combating the progression of Alzheimer’s disease (AD). In this study, we compared the effects of th...

    Authors: Si-Min Song, Qian-Min Liu, Xi Huang, Ping Chen, Min Tao, Xia Pei, Hua-Ning Wang, Yan Han, Jian-Guo Chen, Wei Hong and Zhang-Jin Zhang
    Citation: Alzheimer's Research & Therapy 2025 17:140
    Content type: Research Published on:

  4. Edaravone-Dexborneol (EDB) presents therapeutic effects due to its anti-inflammatory, antioxidant and anti-apoptotic properties, and has been widely used in ischemic stroke. However, the detailed efficacy and ...

    Authors: Rui Mao, Shu Shu, Min Sun, Jiang Chen, Mengsha Hu, Lei Ye, Siyi Xu, Junqiu Jia, Wenxuan Shao, Xinyu Bao, Yun Xu and Xiaolei Zhu
    Citation: Alzheimer's Research & Therapy 2025 17:139
    Content type: Research Published on:

  5. Emerging evidence suggests that senescent microglia play a role in β-amyloid (Aβ) pathology and neuroinflammation in Alzheimer’s disease (AD). Targeting senescent cells with naturally derived compounds exhibit...

    Authors: Ying Liu, Ting Hong, Mingxuan Lv, Xiaoyu Guo, Panpan Zhang, Aijuan Yan and Wenshi Wei
    Citation: Alzheimer's Research & Therapy 2025 17:138
    Content type: Research Published on:

  6. Plasma amyloid-tau-neurodegeneration (ATN) biomarker levels may be influenced by non-brain systems, such as kidney function, which could impact the interpretation of ATN biomarker results, particularly in grou...

    Authors: Natasha Z. Anita, Wassim Tarraf, Sayaka Kuwayama, Freddie Márquez, Charles DeCarli, Bharat Thyagarajan, Nora Franceschini, James P. Lash, Tanya Johns, Kevin A. González, Martha Daviglus, Haibo Zhou, Ariana M. Stickel, Frank J. Penedo, Tatjana Rundek, Doug Galasko…
    Citation: Alzheimer's Research & Therapy 2025 17:137
    Content type: Research Published on:

  7. Age-related macular degeneration (AMD) is the commonest cause of irreversible blindness in developed societies. AMD coincides with advanced age to which genetic and lifestyle factors contribute additional risk...

    Authors: Savannah A. Lynn, Sudha Priya Soundara Pandi, Aida Sanchez-Bretano, Anna-Marie Muir, Lidia Parker, David S. Chatelet, Tutte Newall, Jennifer A. Scott, Eloise Keeling, Neil R. Smyth, Jay E. Self, Andrew J. Lotery, Helena Lee and J. Arjuna Ratnayaka
    Citation: Alzheimer's Research & Therapy 2025 17:136
    Content type: Research Published on:

  8. A proteome-wide association study (PWAS) that integrates proteomic data with genome-wide association study (GWAS) summary data is a powerful tool for studying Alzheimer’s disease (AD) dementia. Existing PWAS a...

    Authors: Tingyang Hu, Qiang Liu, Qile Dai, Aron S. Buchman, David A. Bennett, Shinya Tasaki, Yanling Wang, Nicholas T. Seyfried, Philip L. De Jager, Michael P. Epstein and Jingjing Yang
    Citation: Alzheimer's Research & Therapy 2025 17:135
    Content type: Research Published on:

  9. Event-based modeling (EBM) traces sequential progression of events in complex processes like neurodegenerative diseases, adept at handling uncertainties. This study validated an EBM for Alzheimer’s disease (AD...

    Authors: Mandy M. J. Wittens, Diana M. Sima, Arne Brys, Hanne Struyfs, Ellis Niemantsverdriet, Ellen De Roeck, Christine Bastin, Florence Benoit, Bruno Bergmans, Jean-Christophe Bier, Peter Paul de Deyn, Olivier Deryck, Bernard Hanseeuw, Adrian Ivanoiu, Gaëtane Picard, Eric Salmon…
    Citation: Alzheimer's Research & Therapy 2025 17:134
    Content type: Research Published on:

  10. The growing prevalence of dementia emphasizes the need for effective prevention strategies. Although the partial efficacy of multidomain interventions for dementia prevention has been demonstrated, understandi...

    Authors: Kosuke Fujita, Tetsuaki Kimura, Akiko Yamakawa, Shumpei Niida, Kouichi Ozaki, Takashi Sakurai, Hidenori Arai and Daichi Shigemizu
    Citation: Alzheimer's Research & Therapy 2025 17:130
    Content type: Research Published on:

  11. Agitation is one of the most prevalent neuropsychiatric symptoms leading to institutionalization in individuals with Alzheimer’s disease (AD) dementia. It is associated with poor outcomes, including reduced fu...

    Authors: Anton Bespalov, Jina Swartz, Nadine Knowles and Hans J. Moebius
    Citation: Alzheimer's Research & Therapy 2025 17:133
    Content type: Comment Published on:

  12. Dysregulation retrograde axonal transport in neurons results in autophagosome accumulation, enhancing amyloid β (Aβ) production and accelerating Alzheimer’s disease (AD) progression. Ras-associated GTP-binding...

    Authors: Yangyang Wang, Siyu Li, Xiao Liang, Jianing Fan, Shijie Li, Fanlin Zhou, Xiaoju Li, Mengmeng Lai, Dianmao Feng and Yu Li
    Citation: Alzheimer's Research & Therapy 2025 17:132
    Content type: Research Published on:

  13. Plasma biomarkers offer a promising alternative to amyloid beta (Aβ) positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer’s disease (AD). This cross-sectional stu...

    Authors: Masahito Kubota, Shogyoku Bun, Keisuke Takahata, Shin Kurose, Yuki Momota, Yu Iwabuchi, Toshiki Tezuka, Hajime Tabuchi, Morinobu Seki, Yasuharu Yamamoto, Ryo Shikimoto, Yu Mimura, Takayuki Hoshino, Sho Shimohama, Natsumi Suzuki, Ayaka Morimoto…
    Citation: Alzheimer's Research & Therapy 2025 17:131
    Content type: Research Published on:

  14. Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials with...

    Authors: Glenn A. Harris, Lauren R. Hirschfeld, M. Isabel Gonzalez, Martyn C. Pritchard and Patrick C. May
    Citation: Alzheimer's Research & Therapy 2025 17:129
    Content type: Review Published on:

  15. Emerging evidence indicates that globus pallidus (GP) function can be modulated by orexin-A in movement disorders, while its role in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) remains unclear...

    Authors: Jinghuan Gan, Ziming Xu, Chen Wen, Hao Wu, Zhichao Chen, Zhihong Shi, Hao Lu, Yajie Wang, Shuai Liu and Yong Ji
    Citation: Alzheimer's Research & Therapy 2025 17:128
    Content type: Research Published on:

  16. The adenosine monophosphate-activated protein kinase (AMPK) and its downstream effector Unc-51 like autophagy activating kinase 1 (ULK1) represent a key cellular signaling node, the alteration of which likely ...

    Authors: Arnaud Mary, Samantha Barale, Fanny Eysert, Audrey Valverde, Sandra Lacas-Gervais, Charlotte Bauer, Sabiha Eddarkaoui, Luc Buée, Valérie Buée-Scherrer, Frédéric Checler and Mounia Chami
    Citation: Alzheimer's Research & Therapy 2025 17:127
    Content type: Research Published on:

  17. Magnetic resonance imaging (MRI), combined with artificial intelligence techniques, has improved our understanding of brain structural change and enabled the estimation of brain age. Neurodegenerative disorder...

    Authors: Chenxi Wang, Weiwei Zhang, Ming Ni, Qiong Wang, Chang Liu, Linbin Dai, Mengguo Zhang, Yong Shen and Feng Gao
    Citation: Alzheimer's Research & Therapy 2025 17:126
    Content type: Research Published on:

  18. The diagnosis of Alzheimer’s disease (AD) in its preclinical stages, such as subjective cognitive decline (SCD), is crucial for a timely management of the condition. However, current early diagnostic methods a...

    Authors: Lorenzo Gaetano Amato, Michael Lassi, Alberto Arturo Vergani, Jacopo Carpaneto, Salvatore Mazzeo, Valentina Moschini, Rachele Burali, Giovanni Salvestrini, Carlo Fabbiani, Giulia Giacomucci, Giulia Galdo, Carmen Morinelli, Filippo Emiliani, Maenia Scarpino, Sonia Padiglioni, Benedetta Nacmias…
    Citation: Alzheimer's Research & Therapy 2025 17:125
    Content type: Research Published on:

  19. Although previous studies have shown that specific platelet indices had correlations with cognitive impairment, the associations between platelet indices and cerebrospinal fluid (CSF) biomarkers of Alzheimer’s...

    Authors: Shi-Yin Xiong, Yong-Li Zhao, Yan Fu, Qiong-Yao Li, Quan Hao, Dan-Dan Zhang, Min Liu, Shan Yin, Lan-Yang Wang, Yong-Chang Wang, Shu-Dong Qiu, Zi-Qi Zhang and Lan Tan
    Citation: Alzheimer's Research & Therapy 2025 17:124
    Content type: Research Published on:

  20. Alzheimer’s disease and related dementias (ADRD) take 20 to 30 years to develop, yet setting up studies or registries that take into account the entire disease trajectory is difficult and time consuming. Moreo...

    Authors: Casper de Boer, Hanneke F. M. Rhodius-Meester, Sophie M. van der Landen, Jurgen Claassen, Romy de Haan, Janne M. Papma, Harro Seelaar, Marleen Kloppenburg-Lagendijk, Barbara van Munster, Marjolein de Vugt, Derk Arts, Marco Blom, Tanja J. de Rijke, Miriam Beusink, Robbert Huijsman, Evert-Ben van Veen…
    Citation: Alzheimer's Research & Therapy 2025 17:123
    Content type: Research Published on:

  21. Emerging evidence highlights the bidirectional communication between the gut microbiota and the brain, suggesting a potential role for gut dysbiosis in Alzheimer’s disease (AD) pathology and cognitive decline....

    Authors: Kang-Chen Fan, Chen-Ching Lin, Yen-Ling Chiu, Seong-Ho Koh, Yi-Chien Liu and Yi-Fang Chuang
    Citation: Alzheimer's Research & Therapy 2025 17:122
    Content type: Research Published on:

  22. The hippocampus is highly affected in neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). The relationship between neuropathology and atrophy in hippocampal subfields i...

    Authors: Maud M. A. Bouwman, Irene Frigerio, Chen-Pei Lin, Niels Reijner, Wilma D. J. van de Berg and Laura E. Jonkman
    Citation: Alzheimer's Research & Therapy 2025 17:121
    Content type: Research Published on:

  23. Cognitive impairment, hypertension and diabetes are prevalent chronic conditions in populations of older ages. Previous studies have shown that hypertension and diabetes are risk factors for the development of...

    Authors: Jing Wu, Xiangjun Yin, Weiqiang Ji, Yang Liu, Jing Tang, Han Zhang, Shige Qi, Jie Li, Li Lin, Xueqing Yang, Chengdong Xu and Qingfeng Du
    Citation: Alzheimer's Research & Therapy 2025 17:120
    Content type: Research Published on:

  24. Lecanemab, a monoclonal antibody targeting amyloid beta, has recently been approved for treatment of early-stage Alzheimer’s disease (AD), demonstrating amyloid plaque reduction and slowing of cognitive declin...

    Authors: Noa Bregman, Talya Nathan, Dror Shir, Nurit Omer, Mori Hai Levy, Aya Bar David, Orna Aizenstien, Eyal Lotan, Yifat Alcalay, Anan Abu Awad, Avi Gadoth, Elissa Ash and Tamara Shiner
    Citation: Alzheimer's Research & Therapy 2025 17:119
    Content type: Research Published on:

  25. The rapidly progressive phenotype of Alzheimer’s disease (rpAD) remains a rare and less-studied entity. Therefore, the replication of key results from the rpAD brain and cerebrospinal fluid (CSF) is lacking.

    Authors: Gurkan Bebek, Masaru Miyagi, Xinglong Wang, Brian S. Appleby, James B. Leverenz and Jagan A. Pillai
    Citation: Alzheimer's Research & Therapy 2025 17:118
    Content type: Research Published on:

  26. Dementia with Lewy bodies (DLB) is associated with specific challenges, including heterogeneity in clinical presentation and a less favourable prognosis relative to other dementia subtypes. These challenges ne...

    Authors: Paula Sinead Donnelly, Aoife Sweeney, Anthony P. Passmore, Noleen K. McCorry and Joseph P. M. Kane
    Citation: Alzheimer's Research & Therapy 2025 17:117
    Content type: Review Published on:

  27. Anti-amyloid antibodies for the treatment of Alzheimer´s disease (AD) are currently being evaluated for approval and reimbursement in Europe. An approval brings opportunities, but also challenges to health car...

    Authors: Kristian S. Frederiksen, Mercé Boada, Bruno Dubois, Sebastiaan Engelborghs, Giovanni B. Frisoni, Jean Georges, Jakub Hort, Linus Jönsson, Milica G. Kramberger, Pierre-Jean Ousset, Nikolaos Scarmeas, Reinhold Schmidt, Jonathan M. Schott, Luiza Spiro, Gunhild Waldemar, Bengt Winblad…
    Citation: Alzheimer's Research & Therapy 2025 17:116
    Content type: Review Published on:

  28. Synaptic dysfunction is a relevant feature of Alzheimer’s disease (AD) and Parkinson’s disease (PD) and can be quantified through the measurement of cerebrospinal fluid (CSF) synaptic markers, such as the pres...

    Authors: Lorenzo Gaetani, Giovanni Bellomo, Davide Chiasserini, Charlotte De Rocker, Julie Goossens, Federico Paolini Paoletti, Eugeen Vanmechelen and Lucilla Parnetti
    Citation: Alzheimer's Research & Therapy 2025 17:115
    Content type: Research Published on:

  29. New drugs to treat Alzheimer´s disease (AD) are urgently needed. Human triggering receptor expressed on myeloid cells 2 (hTREM2) is a validated drug target which is genetically associated with AD. Existing ant...

    Authors: Markus Kraller, Julia Faßbender, Ammar Jabali, Joseph Kroeger, Barbara Fink, Bastian Popper, Martin Ungerer and Miriam A. Christlmeier
    Citation: Alzheimer's Research & Therapy 2025 17:114
    Content type: Research Published on:

  31. The use of polygenic risk scores (PRS) for predicting disease risk in Japanese populations, particularly for dementia and related phenotypes, remains markedly unexplored. The aim of this study was to bridge th...

    Authors: Misato Kaishima, Junichi Ito, Kentaro Takahashi, Kenji Tai, Junro Kuromitsu, Shogyoku Bun and Daisuke Ito
    Citation: Alzheimer's Research & Therapy 2025 17:112
    Content type: Research Published on:

  32. Movement patterns, activity levels and circadian rhythm are altered in Alzheimer’s disease (AD) and can be assessed by actigraphy using wearable sensors. We aimed to determine the diagnostic performance of act...

    Authors: Mathias Holsey Gramkow, Andreas Brink-Kjær, Frederikke Kragh Clemmensen, Nikolai Sulkjær Sjælland, Gunhild Waldemar, Poul Jennum, Steen Gregers Hasselbalch and Kristian Steen Frederiksen
    Citation: Alzheimer's Research & Therapy 2025 17:111
    Content type: Research Published on:

  33. Authors: Frederikke Kragh Clemmensen, Mathias Holsey Gramkow, Anja Hviid Simonsen, Nicholas J. Ashton, Hanna Huber, Kaj Blennow, Henrik Zetterberg, Gunhild Waldemar, Steen Gregers Hasselbalch and Kristian Steen Frederiksen
    Citation: Alzheimer's Research & Therapy 2025 17:110
    Content type: Correction Published on:

    The original article was published in Alzheimer's Research & Therapy 2025 17:26

  34. Cannabidiol (CBD), the second most abundant phytocannabinoid in Cannabis sativa, has garnered significant interest due to its non-psychoactive nature and diverse receptor interactions.

    Authors: Iu Raïch, Jaume Lillo, Joan Biel Rebassa, Christian Griñán-Ferré, Aina Bellver-Sanchis, Irene Reyes-Resina, Rafael Franco, Mercè Pallàs and Gemma Navarro
    Citation: Alzheimer's Research & Therapy 2025 17:109
    Content type: Research Published on:

  36. Exploring the early stages of Alzheimer's disease (AD) is crucial for timely intervention to help manage symptoms and set expectations for affected individuals and their families. However, the study of the ear...

    Authors: Ana Lawry Aguila, Luigi Lorenzini, Mohammed Janahi, Frederik Barkhof and Andre Altmann
    Citation: Alzheimer's Research & Therapy 2025 17:107
    Content type: Research Published on:

  37. Mild cognitive impairment (MCI) is a heterogeneous disorder with significant individual variabilities in clinical and biological features. Abnormal inter-regional structural covariance suggests disruption of t...

    Authors: Xiaotong Wei, Ronglong Xiong, Ping Xu, Tingting Zhang, Junjun Zhang, Zhenlan Jin and Ling Li
    Citation: Alzheimer's Research & Therapy 2025 17:106
    Content type: Research Published on:

  38. Hyperexcitability in Alzheimer’s disease (AD) is proposed to emerge early and contribute to disease progression. The dentate gyrus (DG) and its primary cell type, granule cells (GCs) are implicated in hyperexc...

    Authors: David Alcantara-Gonzalez, Meghan Kennedy, Chiara Criscuolo, Justin Botterill and Helen E. Scharfman
    Citation: Alzheimer's Research & Therapy 2025 17:105
    Content type: Research Published on:

  39. Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder clinically characterized by memory decline, cognitive dysfunction, language impairment, deterioration of visuospatial skills, and p...

    Authors: Zihao Deng, Yudi Li, Wenjun Chi, Wanzhou Zhang, Fangming Li and Li Ling
    Citation: Alzheimer's Research & Therapy 2025 17:104
    Content type: Research Published on:

  40. Depression serves as a prodromal symptom of dementia, and individuals with depression exhibit a significantly higher risk of developing dementia. The aim of this study is to develop and validate a novel dement...

    Authors: Xuan Xiao, Yihui Li, Qiaoboyang Wu, Xinting Liu, Xu Cao, Maiping Li, Jianjing Liu, Lianggeng Gong and Xi-jian Dai
    Citation: Alzheimer's Research & Therapy 2025 17:103
    Content type: Research Published on:

  41. Oxysterols, gut metabolites, and N6-methyladenosine (m6A) are extensively implicated in the pathogenesis of cognitive dysfunction, while their alterations in different stages of mild cognitive impairment (MCI)...

    Authors: Wenjing Feng, Mengwei Ju, Tao Wang, Shanshan Cui, Kexin Yang, Zhiting Guo, Miao Liu, Jiaxuan Tao, Huiyan Yu and Rong Xiao
    Citation: Alzheimer's Research & Therapy 2025 17:102
    Content type: Research Published on:

  42. Cognitive frailty (CF) in older adults is a potentially reversible syndrome that may benefit from lifestyle-based multidomain interventions. This study assessed the AGELESS intervention’s impact on cognitive, ...

    Authors: Pavapriya Ponvel, Suzana Shahar, Devinder Kaur Ajit Singh, Arimi Fitri Mat Ludin, Ponnusamy Subramaniam, Norhayati Ibrahim, Hasnah Haron, Aniza Ismail, Chin Ai-Vyrn, Mazlyfarina Mohamad, Hidayah Fadzil, Norhayati Mustafa Khalid, A’isyah Mohammad Safien, Jamilah Mohammad Hanipah, Azyana Ibrahim, Jenni Lehtisalo…
    Citation: Alzheimer's Research & Therapy 2025 17:101
    Content type: Research Published on:

  43. The SorLA protein, encoded by the Sortilin-related receptor 1 (SORL1) gene, is a major player in Alzheimer’s disease (AD) pathophysiology. Functional studies demonstrated that SorLA deficiency results in increase...

    Authors: Romain Castelot, Aline Zarea, David Wallon, Anne Rovelet-Lecrux, Catherine Schramm, Muriel Quillard-Muraine, Anne Beaume, Frédéric Blanc, Olivier Bousiges, Julien Dumurgier, Maïté Formaglio, Gwenael Leguyader, Sylvain Lehmann, Cecilia Marelli, Matthieu Martinet, Leonor Nogueira…
    Citation: Alzheimer's Research & Therapy 2025 17:100
    Content type: Research Published on:

  44. Onset-predictive biomarker tests (OPBT) in genetic frontotemporal dementia (FTD) may be used to recruit mutation carriers into preventive clinical trials before symptoms manifest. This would require disclosure...

    Authors: Charlotte H. Graafland, Harro Seelaar, Jessica L. Panman, Lize C. Jiskoot, Tjitske Kleefstra, Jackie M. Poos, Edo Richard, Maartje H.N. Schermer, John C. van Swieten, Laura Donker Kaat and Eline M. Bunnik
    Citation: Alzheimer's Research & Therapy 2025 17:99
    Content type: Research Published on:

  45. The pathological effects of amyloid β oligomers (Aβo) may be mediated through the metabotropic glutamate receptor subtype 5 (mGluR5), leading to synaptic loss in Alzheimer’s disease (AD). Positron emission tom...

    Authors: Elaheh Salardini, Ryan S. O’Dell, Em Tchorz, Nabeel B. Nabulsi, Yiyun Huang, Richard E. Carson, Christopher H. van Dyck and Adam P. Mecca
    Citation: Alzheimer's Research & Therapy 2025 17:98
    Content type: Research Published on:

  46. Emerging evidence supports the diagnostic and prognostic utility of plasma biomarkers in Alzheimer’s disease (AD), particularly in early disease stages. We sought to extend these findings by evaluating the pro...

    Authors: Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas, Carolyn Revta, James B. Brewer, Gabriel C. Léger, Brianna Askew, Lia Donahue, Stephen Kaplita, Vladimir Coric, Irfan A. Qureshi and Howard H. Feldman
    Citation: Alzheimer's Research & Therapy 2025 17:97
    Content type: Research Published on:

  47. Mutations in the presenilin 1 gene (PSEN1) are well-known causes of early-onset familial Alzheimer’s disease, but they can also present with atypical phenotypes such as pure spastic paraparesis. This study aims t...

    Authors: Kang-Yang Jih, Ting-Rong Hsu, Jong-Ling Fuh, Tse-Hao Lee, Yung-Shuan Lin, Shih-Yu Fang, Yi-Chu Liao and Yi-Chung Lee
    Citation: Alzheimer's Research & Therapy 2025 17:96
    Content type: Research Published on:

  48. The ubiquitin-proteasome system (UPS) is responsible for most protein degradation and its malfunction is normally observed in neurodegenerative diseases, including Alzheimer’s disease (AD). The autocrine motil...

    Authors: Jingjing Zhang, Congcong Liu, Jing Liu, Yuting Cui, Yuli Hou, Qiao Song, Xiaomin Zhang, Xiaoling Wang, Qian Zhang, Min Cao, Wenchao Wang, Peichang Wang and Yaqi Wang
    Citation: Alzheimer's Research & Therapy 2025 17:95
    Content type: Research Published on:

  49. Emerging evidence implicates early dysfunction of dopaminergic neurons in the Ventral Tegmental Area (VTA) as a key contributor to Alzheimer’s Disease (AD) pathophysiology. Specifically, the VTA dopaminergic n...

    Authors: Maria Luisa De Paolis, Gilda Loffredo, Paraskevi Krashia, Livia La Barbera, Annalisa Nobili, Emma Cauzzi, Lucy Babicola, Matteo Di Segni, Roberto Coccurello, Stefano Puglisi-Allegra, Emanuele Claudio Latagliata and Marcello D’Amelio
    Citation: Alzheimer's Research & Therapy 2025 17:94
    Content type: Research Published on:

  50. In Alzheimer’s disease (AD), MRI atrophy patterns can distinguish between amnestic (typical) and non-amnestic (atypical) clinical phenotypes and are increasingly used for diagnosis and outcome measures in clin...

    Authors: Niels Reijner, I. Frigerio, M. M. A. Bouwman, B. D. C. Boon, N. Guizard, T. Jubault, J. J. M. Hoozemans, A. J. M. Rozemuller, F. H. Bouwman, F. Barkhof, E. Gordon, W. D. J. van de Berg and L. E. Jonkman
    Citation: Alzheimer's Research & Therapy 2025 17:93
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193